Vertex expects to finance the acquisition using a combination of cash on hand and debt, supported by $4.5 billion of fully committed bridge financing.
Vertex’s cash, cash equivalents, and total marketable securities as of March 31, 2026, were $13.0 billion.
The transaction was approved by both the Vertex and Crinetics Boards of Directors and is anticipated to close in the third quarter of 2026.
Palsonify And Atumelnant Expand Vertex’s Rare Disease Portfolio
"Crinetics is an excellent strategic fit for Vertex," said Reshma Kewalramani, CEO and President of Vertex.
